Pharmacological evaluation of a novel skeleton compound isobavachin (4′,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity
Bioorganic Chemistry · 2023
DOI: 10.1016/j.bioorg.2023.106405 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2023. Verfasst von Zean Zhao und 17 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceuti…. Hauptthemen laut MEDLINE: Uric Acid, Xanthine Oxidase, Flavones. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Sun Yat-sen University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Previously we discovered a novel natural scaffold compound, isobavachin (4', 7-dihydroxy-8-prenylflavanone), as a potent URAT1 inhibitor by shape and structure based on a virtue screening approach. In this study, further urate-lowering mechanism, pharmacokinetics and toxicities of isobavachin were conducted. Isobavachin inhibited URAT1 with an IC50 value of 0.24 ± 0.06 μM, and residues S35, F365, I481 and R477 of URAT1 contributed to high affinity for isobavachin. Isobavachin also inhibited glucose transporter 9 (GLUT9), another pivotal urate reabsorption transporter, with an IC50 value of 1.12 ± 0.26 μM. Molecular docking and MMGBSA results indicated that isobavachin might compete residues R171, L75 and N333 with uric acid, which leads to inhibition of uric acid transport of GLUT9. Isobavachin weakly inhibited urate secretion transporters OAT1 with an IC50 value of 4.38 ± 1.27 μM, OAT3 with an IC50 of 3.64 ± 0.62 μM, and ABCG2 with an IC50 of 10.45 ± 2.17 μM. Isobavachin also inhibited xanthine oxidase (XOD) activity in vitro with an IC50 value of 14.43 ± 3.56 μM, and inhibited the hepatic XOD activities at 5-20 mg/kg in vivo. Docking and MMGBSA analysis indicated that isobavachin might bind to the Mo-Pt catalyze center of XOD, which leads to inhibition of uric acid production. In vivo, isobavachin exhibited powerful urate-lowering and uricosuric effects at 5-20 mg/kg compared with the positive drugs morin (20 mg/kg) and RDEA3170 (10 mg/kg). Safety assessments revealed that isobavachin was safe and had no obvious toxicities. Isobavachin has little cell toxicity in HK2 cells as indicated by the MTT assay. In vivo, after treatment with 50 mg/kg isobavachin for 14 days, isobavachin had little renal toxicity, as revealed by serum CR/BUN levels, and no hepatotoxicity as revealed by ALT/AST levels. Further HE examination also suggests that isobavachin has no obvious kidney/liver damage. A pharmacokinetic study in SD rats indicated isobavachin had lower bioavailability (12.84 ± 5.13 %) but long half-time (7.04 ± 2.68 h) to maintain a continuous plasma concentration. Collectively, these results indicate that isobavachin deserves further investigation as a candidate anti-hyperuricemic drug with a novel mechanism of action: selective urate reabsorption inhibitor (URAT1/GLUT9) with a moderate inhibitory effect on XOD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, 1838 Guangzhou Avenue North…
- Good clinical Practice Development, Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
- Good clinical Practice Development, Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. Electronic address: zhangq…
Förderung
- Sun Yat-sen University
- National Natural Science Foundation of China
Zitieren
APA
Zhao, Z., Luo, J., Liao, H., Zheng, F., Chen, X., Luo, J., Chen, Y., Zhao, K., Zhang, S., Tian, J., Wu, T., Li, Y., Li, L., Yang, Y., Lin, C., Zhang, Q., Tian, Y., & Pang, J. (2023). Pharmacological evaluation of a novel skeleton compound isobavachin (4′,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2023.106405
Vancouver
Zhao Z, Luo J, Liao H, Zheng F, Chen X, Luo J, et al. Pharmacological evaluation of a novel skeleton compound isobavachin (4′,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity. Bioorganic Chemistry. 2023. doi:10.1016/j.bioorg.2023.106405
BibTeX
@article{Zhao2023,
author = {Zhao, Zean and Luo, Jian and Liao, Hui and Zheng, Fengxin and Chen, Xinhua and Luo, Jiajun and Chen, Yongjun and Zhao, Kunlu and Zhang, Shuqin and Tian, Jinhong and Wu, Ting and Li, Yongmei and Li, Lu and Yang, Yang and Lin, Cuiting and Zhang, Qun and Tian, Yuanxin and Pang, Jianxin},
title = {Pharmacological evaluation of a novel skeleton compound isobavachin (4′,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity},
journal = {Bioorganic Chemistry},
year = {2023},
doi = {10.1016/j.bioorg.2023.106405}
}
EUVIMED